🔗 Share this article

As America undertakes unprecedented changes to its immunization recommendations, an unexpected name has surfaced somewhat surprisingly: Høeg, a US-based physician and epidemiologist who initially gained attention by casting doubt on coronavirus shots throughout the pandemic and has concentrated on possible fatalities after Covid vaccination in her recent position at the FDA.

Planned Overhauls to Childhood Immunization Schedule

Public health authorities planned to unveil radical changes to the childhood vaccination calendar in December, synchronizing the US with Denmark’s vaccine program, according to reports – a substantial departure that would put the US out of step with much of the world with no evidence for benefit. The announcement has been postponed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is listed to present at the event. She was recently named temporary leader of the FDA’s CDER, the fifth person to lead the center this year.

A Shift at the Agency

The acting appointment might represent a strengthened alliance between the pharmaceutical and biologics centers as Høeg and Prasad consolidate power at the regulatory agency – and it signals a greater focus upon rolling back long-standing immunizations at the FDA.

The new acting director has frequently advocated for halting certain pediatric immunization guidelines in the US in order to be more like Denmark, a nation with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccination policy – usually the purview of Dr. Prasad, chief of the FDA’s CBER – rather than drug regulation.

Questions Over Background

The appointee has little discernible background in medication creation, regulation or administrative roles, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and CBER since spring.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in leading a sizeable institution. She lacks background in industry regulation.”

Former commissioners of CBER would “grasp legal statutes and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who headed CBER have had.”

This division has an enormous range of responsibilities at the FDA, she stated.

“Everybody just zeroes in on the innovative therapies, but the generic program approves numerous generic drugs. There’s a biologic copycat branch, OTC medication office and other areas, and every single one have to be supervised,” she explained. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a major management element to the position, which manages over 5,000 staff members. “It is a huge management job, if you execute it properly,” Woodcock concluded.

Response and Contentious Programs

Regarding concerns about Dr. Høeg's qualifications and whether this selection signifies more teamwork among regulatory chiefs on immunizations, a press secretary responded that the “concerns rely on flawed assumptions”.

“Her experience aligns with the responsibilities of her position,” the spokesperson explained, citing the period Dr. Høeg spent guiding the agency head on “medication safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's recently launched fast-track approval initiative, a controversial rapid drug-approval program that apparently concerned her preceding directors. “How are these medications being chosen for this expedited pathway? Who is making the choices?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he said, “the agency seems to be moving towards laxer rules of all drugs, with the exception of immunizations.”

Public Past Work on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if troubling, past, Howard have noted. She authored a analysis using unconfirmed public submissions to determine the frequency of heart inflammation following COVID-19 immunization. She counseled the state of Florida top health official Joseph Ladapo, who reportedly have modified findings to imply Covid vaccinations are pose a greater threat than they are.

Part of her “policy goals” for the current government included altering rules for novel immunizations and halting “non-essential” vaccines, she stated after the election on a podcast. At the agency, Dr. Høeg has reportedly suggested barring adolescent males from receiving Covid vaccinations.

“She is an thorough ideologue who commences with her beliefs and reverse-engineers to accommodate the evidence in a highly disingenuous, fraudulent way,” Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|